JP2017537105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537105A5 JP2017537105A5 JP2017528845A JP2017528845A JP2017537105A5 JP 2017537105 A5 JP2017537105 A5 JP 2017537105A5 JP 2017528845 A JP2017528845 A JP 2017528845A JP 2017528845 A JP2017528845 A JP 2017528845A JP 2017537105 A5 JP2017537105 A5 JP 2017537105A5
- Authority
- JP
- Japan
- Prior art keywords
- humanized antibody
- therapeutic agent
- seq
- intravenous infusion
- subsequent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153317A JP7579227B2 (ja) | 2014-11-26 | 2021-09-21 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| JP2024127719A JP2024161423A (ja) | 2014-11-26 | 2024-08-02 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084815P | 2014-11-26 | 2014-11-26 | |
| US62/084,815 | 2014-11-26 | ||
| PCT/US2015/062705 WO2016086147A1 (en) | 2014-11-26 | 2015-11-25 | Vedolizumab for the treatment of fistulizing crohn's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153317A Division JP7579227B2 (ja) | 2014-11-26 | 2021-09-21 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537105A JP2017537105A (ja) | 2017-12-14 |
| JP2017537105A5 true JP2017537105A5 (enExample) | 2019-01-10 |
Family
ID=54834962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528845A Withdrawn JP2017537105A (ja) | 2014-11-26 | 2015-11-25 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| JP2021153317A Active JP7579227B2 (ja) | 2014-11-26 | 2021-09-21 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| JP2024127719A Pending JP2024161423A (ja) | 2014-11-26 | 2024-08-02 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153317A Active JP7579227B2 (ja) | 2014-11-26 | 2021-09-21 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
| JP2024127719A Pending JP2024161423A (ja) | 2014-11-26 | 2024-08-02 | 瘻孔を伴うクローン病の治療用ベドリズマブ |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170327584A1 (enExample) |
| EP (2) | EP3581585A1 (enExample) |
| JP (3) | JP2017537105A (enExample) |
| WO (1) | WO2016086147A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| EP3581585A1 (en) * | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| CA3027286A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| EP3552632B1 (en) | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medicinal composition for treating and preventing inflammatory bowel disease |
| US12582809B2 (en) | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| AU2020366435A1 (en) * | 2019-10-16 | 2022-04-21 | Morphic Therapeutic, Inc. | Inhibiting human integrin α4β7 |
| JP7805944B2 (ja) | 2020-03-18 | 2026-01-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 瘻孔を治療するための装置及び方法 |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2026019692A2 (en) | 2024-07-15 | 2026-01-22 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory fusion proteins and related methods |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| AU2003298661B2 (en) | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| MX370489B (es) | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
| US20060045872A1 (en) * | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| JP2009515552A (ja) | 2005-11-17 | 2009-04-16 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリン反応性ヒト化免疫グロブリン |
| WO2008150490A2 (en) * | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
| WO2010107752A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| TWI907924B (zh) | 2011-05-02 | 2025-12-11 | 日商武田藥品工業股份有限公司 | 抗-α4β7抗體之調配物 |
| EP3659598A1 (en) * | 2012-06-04 | 2020-06-03 | Gaurav Agrawal | Compositions and methods for treating crohn's disease and related conditions and infections |
| EP3581585A1 (en) * | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| WO2016105572A1 (en) | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| CA3027286A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| WO2018200818A2 (en) | 2017-04-28 | 2018-11-01 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders |
| JP7497159B2 (ja) | 2017-05-26 | 2024-06-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 慢性回腸嚢炎の治療のための方法 |
-
2015
- 2015-11-25 EP EP19174177.6A patent/EP3581585A1/en active Pending
- 2015-11-25 JP JP2017528845A patent/JP2017537105A/ja not_active Withdrawn
- 2015-11-25 EP EP15805720.8A patent/EP3224280A1/en not_active Withdrawn
- 2015-11-25 WO PCT/US2015/062705 patent/WO2016086147A1/en not_active Ceased
- 2015-11-25 US US15/529,308 patent/US20170327584A1/en not_active Abandoned
-
2019
- 2019-03-11 US US16/297,990 patent/US11884731B2/en active Active
-
2021
- 2021-09-21 JP JP2021153317A patent/JP7579227B2/ja active Active
-
2023
- 2023-12-11 US US18/535,781 patent/US20240376210A1/en active Pending
-
2024
- 2024-08-02 JP JP2024127719A patent/JP2024161423A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Picard et al. | Current knowledge and management of hypersensitivity reactions to monoclonal antibodies | |
| JP2015534579A5 (enExample) | ||
| JP2014514346A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2019514974A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| JP2014515763A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| JP2003531129A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2019530713A5 (enExample) | ||
| JP2020504110A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2017535547A5 (enExample) | ||
| Ooi et al. | Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study | |
| JP2015096065A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2018529661A5 (enExample) |